Sunitinib Malate Capsule
Product Images NDC 0093-8199

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sunitinib Malate (NDC 0093-8199). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Image 1)

FDA Label Image

1 (Image 2)

FDA Label Image

1 (Image 3)

The given text shows the results of two treatments Sunitinib Malate and IFN-a on 375 subjects. Sunitinib Malate shows a median of 47.3 weeks of treatment whereas IFN-a shows a median of 22.0 weeks. The Hazard Ratio calculated is 0.42 with a 95% CI (0.32, 0.54). Based on the Progression-Free Survival Probability, Sunitinib Malate shows better results. However, it is important to note that there might have been a significant difference in the treatment methods or processes, which can affect the validity of direct comparison between these treatments.*

FDA Label Image

1 (Image 4)

This text provides data on disease-free survival probability over 6.8 years for a group of 309 subjects treated with Sunitinib malate and a group of 306 subjects treated with a placebo. The hazard ratio between the two groups is 0.76 with a 95% confidence interval of 0.59 to 0.98 and a p-value of 0.03. A graph shows the probability of disease-free survival over time.*

FDA Label Image

1 (Image 5)

This text presents data on the Progression-Free Survival Probability (%) for individuals that received Sunitinib Malate compared to those that received a placebo. The hazard ratio was 0.427, indicating that individuals who received Sunitinib Malate had a significantly lower risk of progression than those who received placebo. The median progression-free survival time for Sunitinib Malate was 10.2 months, whereas the median time for placebo was 5.4 months. The 95% confidence interval for the hazard ratio was 0.271-0.673, and the p-value was 0.0000146. The text also includes a figure showing the percentage of subjects remaining progression-free over time for each treatment group.*

FDA Label Image

1 (Image 6)

This is a medication label for Sunitinib Malate Vsl with a dosage of 12.5mg per capsule. The capsules need to be stored at a temperature range of 68-77°F, and should be kept out of reach of children. The manufacturer of the medication is B. The label includes the NDC number, dosage information, and manufacturing details.*

FDA Label Image

1 (Image 7)

FDA Label Image

1 (Image 8)

FDA Label Image

1 (Image 9)

This is a medication called Sunitinib Malate, which comes in capsule form. The usual dosage for this medication can be found in the accompanying prescribing information. It should be stored between 20°C to 25°C and dispensed in a tightly sealed container, and kept out of reach of children. The manufacturer is Teva Pharmaceuticals USA, Inc. The text includes a prescription number, lot number, and other important information for pharmacists.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.